Carl Zeiss Meditec AG has signaled a downturn, with its financial reports for the first half of the fiscal year 2025/26 revealing a substantial drop in both revenue and earnings. This development has prompted analysts to revise their forecasts, with concerns mounting over the company's immediate profitability and future trajectory.
The company reported adjusted EBITA of €60.5 million, a stark contrast to the €112.6 million recorded in the previous year. Earnings per share also saw a significant slump, standing at €0.17, down from €0.70 year-over-year. Adjusted earnings per share fared little better, falling to €0.48 from €0.81.
On a currency-adjusted basis, revenue is expected to remain broadly stable. However, the underlying weakness in reported figures has led to a general decline in market sentiment. Analysts have noted a small dip in overall sentiment following the recent results, with minor adjustments to revenue estimates and a more pronounced reduction in earnings per share forecasts. JP Morgan analysts highlighted a 4.8% miss on EBITA and a 22.5% miss on EPS for the third quarter, noting that unchanged 2025 guidance is now "caveated with FX headwind risk."
Read More: Australian Chariot Gets Nigerian Lithium Mines, New Era Starts
Measures to Stabilize Operations
In response to these challenges, Carl Zeiss Meditec AG has announced a "comprehensive package of measures" designed to safeguard future growth and earnings potential. The stated aim of these initiatives is to restore an adequate level of earnings power, thereby establishing a foundation for future investments in growth and innovation.
Key components of this plan include strengthening the company's presence in China.
Furthermore, there are plans to expand cost-efficient production capacities outside of China.
External Headwinds Impact Performance
Several external factors have been cited as contributing to the financial strain. Negative currency effects and the introduction of US trade tariffs have significantly impacted the company's performance, particularly in the third quarter. These headwinds have been identified as major drivers behind the disappointing earnings, with particular impact on the Microsurgery division due to lower neurosurgical volumes.
Read More: AI Deepfakes of Royals Spread Fast on TikTok
Analysts at JP Morgan have pointed to continued "softness in China, weaker equipment growth, tariffs," alongside currency effects, as ongoing risks to the full-year outlook.
Analyst Divergence and Market Reaction
Despite the challenges, a degree of divergence exists among analyst valuations, with the most bullish analyst pegging the company's share price at €72.00 and the most bearish at €35.10. Following the recent earnings miss, shares of Carl Zeiss Meditec saw a notable drop, falling 12.7% to their lowest point in nearly eight years, and ranking at the bottom of the European STOXX 600 index.
The company, which operates in medical technology across Germany, Europe, North America, and Asia, is forecast to grow at a rate comparable to the wider industry, factoring in projected growth slowdowns. Nevertheless, the current financial performance and the acknowledged external pressures have introduced a degree of uncertainty regarding its short-to-medium term prospects.
Read More: Hailey Bieber's Rhode Business Grows While Justin Faces Paparazzi
